Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.
作者信息
Daikh David I, St Clair E William
出版信息
Arthritis Care Res (Hoboken). 2012 May;64(5):648-51. doi: 10.1002/acr.21659.
Abstract
摘要
相似文献
1
Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.
Arthritis Care Res (Hoboken). 2012 May;64(5):648-51. doi: 10.1002/acr.21659.
2
Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.
Arthritis Care Res (Hoboken). 2013 May;65(5):832. doi: 10.1002/acr.21873.
3
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
4
Reply: To PMID 22473917.
Arthritis Care Res (Hoboken). 2013 May;65(5):832-3. doi: 10.1002/acr.21872.
5
Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622-3; author reply 1623-4. doi: 10.1002/acr.21809.
6
American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al.
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1622. doi: 10.1002/acr.21770.
7
The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.
Arthritis Rheum. 2008 Jun 15;59(6):757-9. doi: 10.1002/art.23723.
8
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721.
9
The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint.
Z Rheumatol. 2013 Feb;72(1):6-9. doi: 10.1007/s00393-012-1093-6.
引用本文的文献
1
Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study.
Front Immunol. 2023 Feb 28;13:1110992. doi: 10.3389/fimmu.2022.1110992. eCollection 2022.
2
DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.
Nat Commun. 2017 Feb 6;8:14252. doi: 10.1038/ncomms14252.
3
Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials.
Drug Des Devel Ther. 2016 Sep 9;10:2771-2777. doi: 10.2147/DDDT.S91374. eCollection 2016.
4
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.
Arthritis Res Ther. 2013 Oct 25;15(5):R164. doi: 10.1186/ar4347.
5
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.
Pharmaceuticals (Basel). 2012 Aug 10;5(8):802-36. doi: 10.3390/ph5080802.
本文引用的文献
1
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
2
Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1150-6. doi: 10.1097/MEG.0b013e32834bb90a.
3
Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.
Arthritis Rheum. 2012 Jan;64(1):21-32. doi: 10.1002/art.30653.
5
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Arthritis Rheum. 2011 Jul;63(7):1812-22. doi: 10.1002/art.30247.
6
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721.
7
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
BMJ. 2008 Apr 26;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
8
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7. doi: 10.1097/MPG.0b013e31802f6424.
9
The appropriateness method.
Med Decis Making. 2004 Mar-Apr;24(2):228-31. doi: 10.1177/0272989X04264212.
Zotero 插件